Tilray Brands entered this earnings release with the stock already under pressure and down 36% over the past three months. The immediate reaction is muted, with the share price slipping about 1% to US$3.99. That small move sits awkwardly beside a cannabis and consumer products group still posting losses and leaning on valuation appeal rather than profitability.

The main focus is scale versus earnings. Tilray Brands delivered roughly US$915.5m in full year revenue and US$61.1m in adjusted earnings before interest, tax, depreciation and amortization. However, the group also reported a net loss of US$121.4m over the same period. Investors now have to decide whether a low P/S multiple is enough to offset that profit strain.

Is Tilray Brands trading at a rare bargain on its 0.6x P/S, or does continued unprofitability signal a value trap instead? Compare the market story with the underlying numbers in the valuation analysis for Tilray Brands

FY2026 Earnings Summary

• Revenue (Q4 FY2026 vs Q4 FY2025): US$281.7m vs. US$224.5m (revenue increased 25%)
• Net Income or Loss (Q4 FY2026 vs Q4 FY2025): Loss of US$49.6m vs. loss of US$1,272.8m (loss narrowed significantly)
• Basic EPS (Q4 FY2026 vs Q4 FY2025): Loss of US$0.43 per share vs. loss of US$13.01 per share (loss per share narrowed significantly)
• Revenue (Trailing Twelve Months to Q4 FY2026 vs TTM to Q4 FY2025): US$915.5m vs. US$821.3m (revenue increased 11%)

Prefer clean charts over staring at another wall of numbers on Tilray Brands? Get a full visual read on the company, with its valuation front and center, in the company report for Tilray Brands..

Tilray bullish story meets mixed execution test

Bulls argue Tilray Brands is turning scale and diversification into a durable, cash generative consumer platform. The latest year gives some support. Net revenue reached US$915.5m with cannabis, beverage, wellness and pharma distribution all contributing. Adjusted EBITDA of US$61.1m and positive operating cash flow before working capital of about US$18m show the model can produce cash at the operating level. International medical cannabis grew strongly to US$84.9m and CC Pharma revenue reached US$327.2m, which lines up with the thesis that Europe and medical channels can be long term pillars. The balance sheet is cleaner, with roughly US$235m of cash and net debt close to zero. Q4 gross margin of 32% and full year margin around the high 20s indicate some efficiency gains. These are tangible milestones, although not yet enough to fully resolve questions on earnings quality.

Losses and dilution keep Tilray bear case alive

The key bear argument is that Tilray Brands relies on diversification stories and regulatory optionality while core profitability and dilution risk remain unresolved. The company still reported a net loss of US$121.4m for FY2026 and an adjusted free cash outflow of US$86m, so the path to self funded growth is not yet in place. Equity funded moves such as the US$12m debt for equity swap, which issued 2.64m new shares, and use of the ATM program reinforce concerns about ongoing dilution. Cannabis price compression of about US$21m and continued pressure in legacy U.S. craft beverages also fit worries about oversupply and margin strain. The share price is down 36% over 90 days and slipped a further 1% post release, which suggests the market is still focused on these risks rather than the revenue run rate or future partnerships.

After repeated losses and recent dilution, is this just the visible risk, or are there deeper structural pressure points ahead? Review the risk analysis for Tilray Brands which shows 2 important warning signs.

Take Control Of Your Next Move

If Tilray Brands' mix of revenue scale, ongoing losses and dilution risk has your attention, register for free with Simply Wall St and add it to a Watchlist to keep an eye on price versus fair value and wait for a setup that fits your plan. Once you decide to take a position, use the Portfolio Command Center to cut through noise and focus on the updates that matter for your holdings. For longer term conviction, tap into crowd insights and different angles on Tilray Brands through the Community. Spot potential catalysts and red flags early so you can stay ahead of the broader market, not react to it.

Seeking Alternatives Beyond Tilray Brands

Fresh ideas do not sit still. While attention clusters around Tilray Brands, other stocks may be building breakout momentum under the radar for now. Do not delay and consider getting in early.

• Capture potential breakouts in overlooked quality by scanning the curated 21 high quality undiscovered gems before the crowd catches on and prices move away from your ideal entry zone.
• Target resilient compounding potential with a focused sweep of 85 resilient stocks with low risk scores so you can focus on steadier profiles while stress is still priced into weaker stocks.
• Ride structural momentum in critical resources through a filtered set of 8 top copper producer stocks while these producers remain under the radar for now and sentiment has not fully caught up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.